Here are five quick updates:
• Brean Capital gave LDR a “buy”
• One-year target price was set at $50
• LDR has differentiated products, boosting potential
• JMP Securities maintains its “market outperform”
• Piper Jaffray initiated coverage in January at “overweight
“Given the degree of differentiation and the potential for LDRH’s cervical disc technology to disrupt the current cervical fusion market, we think this is a unique company with a significantly better growth profile than its small- to mid-cap peers,” according to Mr. Wittes.
LDR has both cervical disc replacement and fusion technologies. The company’s Mobi-C disc is the only cervical disc with FDA clearance for two-level disc replacement procedures.
More articles on spine devices:
6 key updates on Aurora Spine’s 1st trache of non-brokered private placement
Nasdaq to Amedica: Higher stock price necessary to stay listed—6 key notes
LDR, Amendia, Precision Spine & more—18 key notes
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
